Prima Implant Restores Vision for Over 40 Patients
Science Corp, founded by Neuralink co-founder Max Hodak, has successfully restored coherent vision for more than 40 blind individuals through its Prima implant. In a large-scale clinical trial with results published in the New England Journal of Medicine, the 2mm x 2mm silicon chip implanted beneath the retina demonstrated its ability to generate formed images in patients' minds. This marks a significant advance over previous technologies, such as those from Second Sight, which could only produce sporadic light flashes. The Prima system works by using a camera mounted on glasses to capture the environment and a laser to project that image onto the implant, which then stimulates the eye's bipolar cells, bypassing the damaged photoreceptors.
Hodak Pivots to 'Neuro-Engineering' Over Drug Discovery
The breakthrough champions what Hodak calls 'neuro-engineering'—a paradigm that treats the brain as a computer and focuses on building interfaces to input signals directly. This approach circumvents the decades-long timelines and high failure rates common in traditional pharmaceutical or gene therapy development. Instead of attempting to fix the cellular reason for blindness, Science's technology bypasses the issue to feed visual data back into the system. This strategy reflects a deep convergence between artificial intelligence and neuroscience, where insights from building AI models are directly informing how to interface with the brain's own 'latent space' or internal representations.
Neuroscience and AI are undergoing a deep convergence.
— Max Hodak, Founder, Science Corp.
'Bio-Hybrid' Interfaces Are The Next Frontier
Looking ahead, Hodak outlined a vision for 'bio-hybrid' neural interfaces that could create unprecedented connections with the brain. The goal is to move beyond metal electrodes by engineering implants that contain living neurons derived from stem cells. These neurons would be designed to physically integrate with the patient's brain, growing together to form a stable, high-bandwidth biological connection. Science is developing universal, 'low-immunogenicity' cell lines to avoid rejection and make the technology scalable. This method could enable entirely new capabilities, such as an 'internet nerve' that directly links human consciousness to digital information, fundamentally altering the human-machine interface.
